Port Site Hernias Following Laparoscopic Ventral Hernia Repair.


Journal

World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052

Informations de publication

Date de publication:
Dec 2020
Historique:
accepted: 16 08 2020
pubmed: 3 9 2020
medline: 22 6 2021
entrez: 3 9 2020
Statut: ppublish

Résumé

Port site hernias (PSH) are underreported following laparoscopic ventral hernia repair (LVHR). Most occur at the site of laterally placed 10-12-mm ports used to introduce large pieces of mesh. One alternative is to place the large port through the ventral hernia defect; however, there is potential for increased risk of surgical site infection (SSI). This study evaluates the outcomes when introducing mesh through a 10-12-mm port placed through the hernia defect. This was a retrospective case series of patients who underwent LVHR in three prospective trials from 2014-2017 at one institution. All patients had mesh introduced through a 10-12-mm port placed through the ventral hernia defect. The primary outcome was SSI. Secondary outcomes were hernia occurrences including recurrences and PSH. A total of 315 eligible patients underwent LVHR with a median (range) follow-up of 21 (11-41) months. Many patients were obese (66.9%), recently quit tobacco use (8.8%), or had diabetes (18.9%). Most patients had an incisional hernia (61.2%), and 19.2% were recurrent. Hernias were on average 4.8 ± 3.8 cm in width. Two patients (0.6%) had an SSI. Fourteen patients had a hernia occurrence-13 (4.4%) had a recurrent hernia, and one patient (0.3%) had a PSH. During LVHR, introduction of mesh through a 10-12-mm port placed through the hernia defect is associated with a low risk of SSI and low risk of hernia occurrence. While further studies are needed to confirm these results, mesh can be safely introduced through a port through the defect.

Sections du résumé

BACKGROUND BACKGROUND
Port site hernias (PSH) are underreported following laparoscopic ventral hernia repair (LVHR). Most occur at the site of laterally placed 10-12-mm ports used to introduce large pieces of mesh. One alternative is to place the large port through the ventral hernia defect; however, there is potential for increased risk of surgical site infection (SSI). This study evaluates the outcomes when introducing mesh through a 10-12-mm port placed through the hernia defect.
METHODS METHODS
This was a retrospective case series of patients who underwent LVHR in three prospective trials from 2014-2017 at one institution. All patients had mesh introduced through a 10-12-mm port placed through the ventral hernia defect. The primary outcome was SSI. Secondary outcomes were hernia occurrences including recurrences and PSH.
RESULTS RESULTS
A total of 315 eligible patients underwent LVHR with a median (range) follow-up of 21 (11-41) months. Many patients were obese (66.9%), recently quit tobacco use (8.8%), or had diabetes (18.9%). Most patients had an incisional hernia (61.2%), and 19.2% were recurrent. Hernias were on average 4.8 ± 3.8 cm in width. Two patients (0.6%) had an SSI. Fourteen patients had a hernia occurrence-13 (4.4%) had a recurrent hernia, and one patient (0.3%) had a PSH.
CONCLUSION CONCLUSIONS
During LVHR, introduction of mesh through a 10-12-mm port placed through the hernia defect is associated with a low risk of SSI and low risk of hernia occurrence. While further studies are needed to confirm these results, mesh can be safely introduced through a port through the defect.

Identifiants

pubmed: 32875356
doi: 10.1007/s00268-020-05757-y
pii: 10.1007/s00268-020-05757-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4093-4097

Auteurs

Naila H Dhanani (NH)

Department of Surgery, Lyndon B. Johnson General Hospital, McGovern Medical School at UTHealth, 5656 Kelley St, Houston, TX, 77026, USA. naila.dhanani@uth.tmc.edu.

Karla Bernardi (K)

Department of Surgery, Lyndon B. Johnson General Hospital, McGovern Medical School at UTHealth, 5656 Kelley St, Houston, TX, 77026, USA.

Oscar A Olavarria (OA)

Department of Surgery, Lyndon B. Johnson General Hospital, McGovern Medical School at UTHealth, 5656 Kelley St, Houston, TX, 77026, USA.

Deepa Cherla (D)

Department of Surgery, Lyndon B. Johnson General Hospital, McGovern Medical School at UTHealth, 5656 Kelley St, Houston, TX, 77026, USA.

Lillian S Kao (LS)

Department of Surgery, Lyndon B. Johnson General Hospital, McGovern Medical School at UTHealth, 5656 Kelley St, Houston, TX, 77026, USA.

Tien C Ko (TC)

Department of Surgery, Lyndon B. Johnson General Hospital, McGovern Medical School at UTHealth, 5656 Kelley St, Houston, TX, 77026, USA.

Mike K Liang (MK)

Department of Surgery, Lyndon B. Johnson General Hospital, McGovern Medical School at UTHealth, 5656 Kelley St, Houston, TX, 77026, USA.

Julie L Holihan (JL)

Department of Surgery, Lyndon B. Johnson General Hospital, McGovern Medical School at UTHealth, 5656 Kelley St, Houston, TX, 77026, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH